BRPI0810096A2 - Anticorpo anti-epcam e seus usos - Google Patents

Anticorpo anti-epcam e seus usos

Info

Publication number
BRPI0810096A2
BRPI0810096A2 BRPI0810096-9A2A BRPI0810096A BRPI0810096A2 BR PI0810096 A2 BRPI0810096 A2 BR PI0810096A2 BR PI0810096 A BRPI0810096 A BR PI0810096A BR PI0810096 A2 BRPI0810096 A2 BR PI0810096A2
Authority
BR
Brazil
Prior art keywords
epcam antibody
therapeutic
designated
high affinity
shows high
Prior art date
Application number
BRPI0810096-9A2A
Other languages
English (en)
Inventor
Anna Maria Anastasi
Fiorella Petronzelli
Rita De Santis
Saverio Alberti
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of BRPI0810096A2 publication Critical patent/BRPI0810096A2/pt
Publication of BRPI0810096A8 publication Critical patent/BRPI0810096A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0810096A 2007-04-04 2008-04-02 Anticorpo anti-epcam e seus usos BRPI0810096A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07105628 2007-04-04
PCT/EP2008/053913 WO2008122551A2 (en) 2007-04-04 2008-04-02 Anti-epcam antibody and uses thereof

Publications (2)

Publication Number Publication Date
BRPI0810096A2 true BRPI0810096A2 (pt) 2014-10-21
BRPI0810096A8 BRPI0810096A8 (pt) 2017-12-26

Family

ID=38458122

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810096A BRPI0810096A8 (pt) 2007-04-04 2008-04-02 Anticorpo anti-epcam e seus usos

Country Status (21)

Country Link
US (1) US8318911B2 (pt)
EP (1) EP2142570B1 (pt)
JP (1) JP5631733B2 (pt)
KR (1) KR101683884B1 (pt)
CN (1) CN101970497B (pt)
AT (1) ATE512988T1 (pt)
AU (1) AU2008235566B2 (pt)
BR (1) BRPI0810096A8 (pt)
CA (1) CA2682296C (pt)
CY (1) CY1111819T1 (pt)
DK (1) DK2142570T3 (pt)
EA (1) EA023679B1 (pt)
ES (1) ES2367675T3 (pt)
HR (1) HRP20110620T1 (pt)
IL (1) IL201196A0 (pt)
MX (1) MX2009010444A (pt)
PL (1) PL2142570T3 (pt)
PT (1) PT2142570E (pt)
RS (1) RS52040B (pt)
SI (1) SI2142570T1 (pt)
WO (1) WO2008122551A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1585974B1 (en) 2003-01-24 2013-02-27 University of Utah Methods of predicting mortality risk by determining telomere length
CN107083444B (zh) 2008-12-22 2023-03-14 犹他大学研究基金会 单色多重定量pcr
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
DK3138581T3 (en) 2011-03-17 2019-04-15 Univ Birmingham REDIRECTED IMMUNTERY
US9541480B2 (en) 2011-06-29 2017-01-10 Academia Sinica Capture, purification, and release of biological substances using a surface coating
JP6163502B2 (ja) * 2012-03-02 2017-07-12 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗上皮細胞接着分子（ＥｐＣＡＭ）抗体及びその使用方法
US9494500B2 (en) 2012-10-29 2016-11-15 Academia Sinica Collection and concentration system for biologic substance of interest and use thereof
CA2912216A1 (en) 2013-05-22 2014-11-27 Telomere Diagnostics, Inc. Measures of short telomere abundance
TW201623605A (zh) 2014-04-01 2016-07-01 中央研究院 用於癌症診斷及預後之方法及系統
TW201612308A (en) 2014-08-26 2016-04-01 Academia Sinica Collector architecture layout design
JP2018501799A (ja) 2014-12-30 2018-01-25 テロメア ダイアグノスティクス インコーポレイテッド マルチプレックス定量的ｐｃｒ
US11098131B2 (en) 2015-07-31 2021-08-24 Sutro Biopharma, Inc. Anti-EpCAM antibodies, compositions comprising anti-EpCAM antibodies and methods of making and using anti-EpCAM antibodies
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
EP3436480A4 (en) * 2016-03-30 2019-11-27 Musc Foundation for Research Development METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
US20190262397A1 (en) 2016-07-26 2019-08-29 Tessa Therapeutics Pte. Ltd. Chimeric antigen receptor
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
EP3897851A2 (en) 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager
TW202039582A (zh) * 2019-04-22 2020-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ＥｐＣＡＭ抗體及其應用
KR102560876B1 (ko) * 2019-06-11 2023-07-28 바이오아트라, 인코퍼레이티드 조건부 활성 항-epcam 항체, 항체 단편, 이들의 면역접합체 및 이의 용도
CN110950959B (zh) * 2020-02-25 2020-07-03 和铂医药(上海)有限责任公司 靶向EpCAM的抗体及其制备和应用
CN112094350B (zh) * 2020-06-01 2024-01-05 普众发现医药科技(上海)有限公司 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd326的单克隆抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) * 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
IT1245748B (it) 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
JP3427871B2 (ja) * 1996-06-24 2003-07-22 戸田工業株式会社 コバルト被着型針状磁性酸化鉄粒子粉末
ITRM20010079A1 (it) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
US7435804B2 (en) 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b

Also Published As

Publication number Publication date
KR20100016237A (ko) 2010-02-12
WO2008122551A9 (en) 2009-02-05
JP2010523096A (ja) 2010-07-15
AU2008235566B2 (en) 2013-06-06
ATE512988T1 (de) 2011-07-15
HRP20110620T1 (hr) 2011-09-30
CN101970497A (zh) 2011-02-09
CA2682296C (en) 2017-02-28
EP2142570A2 (en) 2010-01-13
DK2142570T3 (da) 2011-10-03
RS52040B (en) 2012-04-30
IL201196A0 (en) 2010-05-17
PT2142570E (pt) 2011-09-13
EP2142570B1 (en) 2011-06-15
ES2367675T3 (es) 2011-11-07
BRPI0810096A8 (pt) 2017-12-26
EA023679B1 (ru) 2016-06-30
WO2008122551A2 (en) 2008-10-16
SI2142570T1 (sl) 2012-01-31
EA200970923A1 (ru) 2010-04-30
US8318911B2 (en) 2012-11-27
MX2009010444A (es) 2009-10-20
KR101683884B1 (ko) 2016-12-07
CY1111819T1 (el) 2015-10-07
PL2142570T3 (pl) 2011-11-30
CA2682296A1 (en) 2008-10-16
JP5631733B2 (ja) 2014-11-26
AU2008235566A1 (en) 2008-10-16
US20100092491A1 (en) 2010-04-15
CN101970497B (zh) 2017-05-10
WO2008122551A3 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
BRPI0810096A2 (pt) Anticorpo anti-epcam e seus usos
MX2019010972A (es) Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
GEP20237480B (en) Antibodies against signal-regulatory protein alpha and methods of use
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
BR112018002844A2 (pt) receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos
CU20120095A7 (es) Antagonistas de pcsk9
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
UA113712C2 (xx) Антитіло до fap і способи його застосування
ECSP088508A (es) Antagonistas de neuropilina
EA200870129A1 (ru) Человеческие антитела против il-23, композиции, способы и применение
WO2016210365A3 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
EA201100694A1 (ru) Антитело к cd38 человека и его применение
MX2009008926A (es) Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1.
BR112012007523A2 (pt) moléculas de anticorpo anti-gcc e composições e métodos relacionados
EP2542581A4 (en) SPECIFIC APOLIPOPROTEIN ANTIBODY AND METHODS OF USING SAME
MX2019011624A (es) Metodos y composiciones para la reduccion de la inmunogenicidad.
TN2019000225A1 (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
CR10143A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
CR20200313A (es) VARIANTES DE DOMINIO DE Fc DE IgG HUMANA CON FUNCIÓN EFECTIVA MEJORADA
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
WO2017015634A3 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
TR201900550T4 (tr) İnsan p53'ünün bir lineer epitopunu bağlayan antikor ve bunun tanısal uygulamaları.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALFASIGMA S.P.A. (IT)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B350 Update of information on the portal [chapter 15.35 patent gazette]